Wendy Yarno - Global Blood Director
GBTDelisted Stock | USD 68.49 0.00 0.00% |
Director
Ms. Wendy L. Yarno is Independent Director of the company. Ms. Yarno retired in September 2008 from Merck Co, Inc. where she served in commercial and human resource positions of increasing seniority, most recently as Chief Marketing Officer, before she retired. Prior to this position, Ms. Yarno served as General Manager for Mercks CardiovascularMetabolic United States Business Unit and as Senior Vice President, Human Resources. From 2010 to 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno currently serves on the boards of directors of the biopharmaceuticals companies Alder BioPharmaceuticals, Inc., MyoKardia, Inc. and Inovio Pharmaceuticals, Inc., and Aratana Therapeutics, Inc., a pet therapeutics company. Ms. Yarno previously served as member of the board of directors of St. Jude Medical, Inc., a medical device company, from 2002 until January 2017 when St. Jude Medical was acquired by Abbott Laboratories Medivation, Inc., a biopharmaceutical company, from April 2013 until September 2016 when Medivation was acquired by Pfizer Inc. and Durata Therapeutics, Inc., a pharmaceutical company, from August 2014 until November 2014 when Durata was acquired by Actavis plc. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business, and a B.S. in business administration from Portland State University. Ms. Yarnos qualifications to serve on our Board of Directors include her extensive experience commercializing pharmaceutical products, and her extensive operational and senior management experience, in the biopharmaceutical industry, as well as her experience serving on the board of directors of other biopharmaceutical companies. since 2017.
Age | 63 |
Tenure | 7 years |
Professional Marks | MBA |
Phone | 650 741-7700 |
Web | www.globalbloodtx.com |
Wendy Yarno Latest Insider Activity
Tracking and analyzing the buying and selling activities of Wendy Yarno against Global Blood stock is an integral part of due diligence when investing in Global Blood. Wendy Yarno insider activity provides valuable insight into whether Global Blood is net buyers or sellers over its current business cycle. Note, Global Blood insiders must abide by specific rules, including filing SEC forms every time they buy or sell Global Blood'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Wendy Yarno over a year ago Exercise or conversion by Wendy Yarno of 2300 shares of MyoKardia subject to Rule 16b-3 |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
C Chambliss | Primerica | 76 | |
Craig Hatkoff | SL Green Realty | 66 | |
Robert Yost | Marsh McLennan Companies | 73 | |
James Dingman | ICC Holdings | 64 | |
Michael Glimcher | MI Homes | 52 | |
Sharen Turney | MI Homes | ||
Thomas Mason | MI Homes | 60 | |
William Carter | MI Homes | 67 | |
John Alschuler | SL Green Realty | 72 | |
Lauren Dillard | SL Green Realty | 44 | |
Nancy Kramer | MI Homes | 64 | |
Betsy Atkins | SL Green Realty | 68 | |
Cynthia Day | Primerica | 55 | |
Norman Traeger | MI Homes | 80 | |
Daniel Portes | ICC Holdings | 64 | |
Mark Schwab | ICC Holdings | 68 | |
Rickey Plunkett | ICC Holdings | 62 | |
Steven Mills | Marsh McLennan Companies | 69 | |
Friedrich Bohm | MI Homes | 78 | |
Christine Schmitt | ICC Holdings | 61 | |
Edwin Burton | SL Green Realty | 77 |
Management Performance
Return On Equity | -124.53 | |||
Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
Michael Bonney, Director | ||
Stephanie Yao, IR Contact Officer | ||
Myesha Lacy, IR Contact Officer | ||
Mark Perry, Independent Director | ||
Jeffrey Farrow, CFO | ||
Myesha Edwards, IR Contact Officer | ||
Philip Pizzo, Director | ||
Glenn Pierce, Director | ||
Willie Brown, Independent Director | ||
Wendy Yarno, Director | ||
Kevin Starr, Director | ||
Hing Sham, Senior Vice President - Chemistry | ||
Scott Morrison, Director | ||
Deval Patrick, Independent Director | ||
Tricia Suvari, Chief Legal Officer | ||
Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
David Johnson, Chief Commercial Officer | ||
Charles Homcy, Director | ||
Dawn Svoronos, Director | ||
Ted Love, President CEO, Director | ||
Eleanor Ramos, Chief Medical Officer | ||
John Schembri, Vice President of Finance and Administration | ||
Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -124.53 | |||
Return On Asset | -23.82 | |||
Profit Margin | (146.82) % | |||
Operating Margin | (137.33) % | |||
Current Valuation | 2.24 B | |||
Shares Outstanding | 64.45 M | |||
Shares Owned By Insiders | 2.72 % | |||
Shares Owned By Institutions | 97.28 % | |||
Number Of Shares Shorted | 9.23 M | |||
Price To Earning | (13.97) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Global Blood in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Global Blood's short interest history, or implied volatility extrapolated from Global Blood options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |